Alnylam Historical Cash Flow
| ALNY Stock | USD 268.46 2.56 0.94% |
Analysis of Alnylam Pharmaceuticals cash flow over time is an excellent tool to project Alnylam Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 855.6 M or Other Cashflows From Financing Activities of 235.9 M as it is a great indicator of Alnylam Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Alnylam Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Alnylam Pharmaceuticals is a good buy for the upcoming year.
Alnylam |
About Alnylam Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Alnylam balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Alnylam's non-liquid assets can be easily converted into cash.
Alnylam Pharmaceuticals Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Alnylam Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Alnylam Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Alnylam Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Total Cashflows From Investing Activities is fairly stable compared to the past year. Other Cashflows From Investing Activities is likely to rise to about 60.6 M in 2025, whereas Free Cash Flow is likely to drop (44.7 M) in 2025.
Alnylam Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Alnylam Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alnylam Pharmaceuticals cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (50.6M) | 323.1M | 46.4M | (53.7M) | 153.8M | 161.5M | |
| Free Cash Flow | (685.3M) | (718.1M) | (613.3M) | 41.9M | (42.6M) | (44.7M) | |
| Change In Working Capital | (12.7M) | (162.8M) | (35.6M) | 10.8M | (214.1M) | (203.4M) | |
| Begin Period Cash Flow | 549.6M | 499.0M | 822.2M | 868.6M | 814.9M | 855.6M | |
| Other Cashflows From Financing Activities | 695.5M | 747.1M | 171.7M | 172.1M | 294.2M | 235.9M | |
| Depreciation | 74.4M | 89.7M | 85.6M | 97.0M | 56.7M | 59.5M | |
| Other Non Cash Items | 95.8M | 174.2M | 309.2M | 214.9M | 47.9M | 53.0M | |
| Capital Expenditures | 70.4M | 76.4M | 72.1M | 62.2M | 34.3M | 39.9M | |
| Total Cash From Operating Activities | (615.0M) | (641.7M) | (541.3M) | 104.2M | (8.3M) | (8.7M) | |
| Net Income | (858.3M) | (852.8M) | (1.1B) | (440.2M) | (278.2M) | (292.1M) | |
| Total Cash From Financing Activities | 995.0M | 1.2B | 425.8M | 172.1M | 294.2M | 351.7M | |
| End Period Cash Flow | 499.0M | 822.2M | 868.6M | 814.9M | 968.7M | 1.0B | |
| Change To Liabilities | 92.4M | 143.7M | 88.2M | 191.8M | 220.5M | 231.6M | |
| Stock Based Compensation | 139.9M | 165.7M | 230.6M | 221.7M | 272.1M | 285.7M | |
| Change To Account Receivables | (56.2M) | (101.8M) | (45.6M) | (87.9M) | (86.6M) | (82.2M) | |
| Change To Netincome | 201.8M | 156.7M | 223.4M | 307.7M | 353.9M | 371.6M | |
| Total Cashflows From Investing Activities | (417.7M) | (435.5M) | (273.3M) | 169.4M | 152.4M | 160.0M | |
| Other Cashflows From Investing Activities | (31.2M) | (4.4M) | (13.2M) | (4.4M) | 57.8M | 60.6M | |
| Sale Purchase Of Stock | 853.2M | 300.0M | 246.3M | 259.4M | 298.3M | 313.2M | |
| Change To Inventory | (35.4M) | (26.4M) | (34.1M) | 18.4M | 13.6M | 14.3M | |
| Investments | (334.0M) | (192.6M) | 169.4M | (235.6M) | (116.8M) | (122.7M) | |
| Change Receivables | (24.2M) | (56.2M) | (101.8M) | (45.6M) | (41.0M) | (39.0M) | |
| Cash And Cash Equivalents Changes | 127.1M | (55.5M) | 332.1M | 53.8M | 61.9M | 62.7M | |
| Cash Flows Other Operating | 353.0M | (204K) | (19.9M) | 125.7M | 144.5M | 151.7M | |
| Change To Operating Activities | (25.6M) | (20.8M) | (72.4M) | (81.7M) | (73.5M) | (69.8M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.